Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 1.65
JNJ's Cash to Debt is ranked lower than
55% of the 692 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.66 vs. JNJ: 1.65 )
Ranked among companies with meaningful Cash to Debt only.
JNJ' s 10-Year Cash to Debt Range
Min: 0.37  Med: 1.55 Max: 6.28
Current: 1.65
0.37
6.28
Equity to Asset 0.53
JNJ's Equity to Asset is ranked lower than
64% of the 551 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.63 vs. JNJ: 0.53 )
Ranked among companies with meaningful Equity to Asset only.
JNJ' s 10-Year Equity to Asset Range
Min: 0.49  Med: 0.56 Max: 0.67
Current: 0.53
0.49
0.67
Interest Coverage 39.32
JNJ's Interest Coverage is ranked lower than
66% of the 370 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 933.44 vs. JNJ: 39.32 )
Ranked among companies with meaningful Interest Coverage only.
JNJ' s 10-Year Interest Coverage Range
Min: 23.47  Med: 38.33 Max: 230.91
Current: 39.32
23.47
230.91
F-Score: 6
Z-Score: 5.24
M-Score: -2.64
WACC vs ROIC
9.78%
27.12%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 28.10
JNJ's Operating margin (%) is ranked higher than
92% of the 652 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.76 vs. JNJ: 28.10 )
Ranked among companies with meaningful Operating margin (%) only.
JNJ' s 10-Year Operating margin (%) Range
Min: 18.63  Med: 24.37 Max: 28.2
Current: 28.1
18.63
28.2
Net-margin (%) 21.63
JNJ's Net-margin (%) is ranked higher than
89% of the 652 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.85 vs. JNJ: 21.63 )
Ranked among companies with meaningful Net-margin (%) only.
JNJ' s 10-Year Net-margin (%) Range
Min: 12.52  Med: 17.30 Max: 21.96
Current: 21.63
12.52
21.96
ROE (%) 21.58
JNJ's ROE (%) is ranked higher than
83% of the 677 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.87 vs. JNJ: 21.58 )
Ranked among companies with meaningful ROE (%) only.
JNJ' s 10-Year ROE (%) Range
Min: 17.02  Med: 27.06 Max: 30.17
Current: 21.58
17.02
30.17
ROA (%) 12.05
JNJ's ROA (%) is ranked higher than
82% of the 697 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.99 vs. JNJ: 12.05 )
Ranked among companies with meaningful ROA (%) only.
JNJ' s 10-Year ROA (%) Range
Min: 8.93  Med: 15.24 Max: 17.94
Current: 12.05
8.93
17.94
ROC (Joel Greenblatt) (%) 92.04
JNJ's ROC (Joel Greenblatt) (%) is ranked higher than
92% of the 694 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 11.80 vs. JNJ: 92.04 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
JNJ' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 46.33  Med: 84.68 Max: 112.6
Current: 92.04
46.33
112.6
Revenue Growth (3Y)(%) 3.50
JNJ's Revenue Growth (3Y)(%) is ranked lower than
60% of the 534 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.80 vs. JNJ: 3.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
JNJ' s 10-Year Revenue Growth (3Y)(%) Range
Min: 1.4  Med: 7.20 Max: 14.8
Current: 3.5
1.4
14.8
EBITDA Growth (3Y)(%) 14.60
JNJ's EBITDA Growth (3Y)(%) is ranked higher than
67% of the 476 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.80 vs. JNJ: 14.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
JNJ' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -6.6  Med: 10.10 Max: 16.5
Current: 14.6
-6.6
16.5
EPS Growth (3Y)(%) 17.80
JNJ's EPS Growth (3Y)(%) is ranked higher than
69% of the 447 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.80 vs. JNJ: 17.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
JNJ' s 10-Year EPS Growth (3Y)(%) Range
Min: -8.6  Med: 10.00 Max: 20.2
Current: 17.8
-8.6
20.2
» JNJ's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

JNJ Guru Trades in Q2 2014

Paul Tudor Jones 5,700 sh (+42.50%)
John Rogers 522,727 sh (+42.46%)
Richard Pzena 1,155,666 sh (+33.12%)
Sarah Ketterer 837,250 sh (+20.23%)
Jim Simons 3,145,500 sh (+18.29%)
Pioneer Investments 4,329,534 sh (+11.26%)
RS Investment Management 7,928 sh (+9.68%)
Ken Fisher 10,448,448 sh (+4.72%)
John Buckingham 46,512 sh (+1.78%)
Manning & Napier Advisors, Inc 4,769,286 sh (+0.89%)
James Barrow 17,065,230 sh (+0.66%)
First Eagle Investment 1,623,482 sh (+0.37%)
Ruane Cunniff 76,012 sh (+0.29%)
Tom Gayner 574,200 sh (unchged)
Prem Watsa 84,700 sh (unchged)
Richard Snow 3,245 sh (unchged)
Michael Price 35,000 sh (unchged)
Dodge & Cox 38,625 sh (unchged)
Richard Perry 342,277 sh (unchged)
Yacktman Fund 4,050,000 sh (unchged)
Tweedy Browne Global Value 865,835 sh (unchged)
Caxton Associates 100,000 sh (unchged)
Warren Buffett 327,100 sh (unchged)
Brian Rogers 4,633,000 sh (unchged)
Joel Greenblatt Sold Out
Chuck Royce Sold Out
PRIMECAP Management 12,242,420 sh (-0.48%)
Bill Frels 1,996,199 sh (-0.76%)
Tweedy Browne 4,196,224 sh (-1.71%)
Murray Stahl 31,683 sh (-2.00%)
Jeff Auxier 94,101 sh (-3.23%)
First Pacific Advisors 1,851,700 sh (-4.36%)
Steven Romick 1,750,000 sh (-4.63%)
Donald Yacktman 9,045,902 sh (-5.50%)
Mario Gabelli 373,186 sh (-5.54%)
Yacktman Focused Fund 3,300,000 sh (-13.16%)
Jeremy Grantham 14,297,233 sh (-18.65%)
Robert Olstein 87,000 sh (-20.91%)
John Hussman 1,325 sh (-50.00%)
George Soros 50,000 sh (-51.22%)
HOTCHKIS & WILEY 1,426,614 sh (-63.73%)
Ray Dalio 65,893 sh (-74.94%)
» More
Q3 2014

JNJ Guru Trades in Q3 2014

Joel Greenblatt 14,319 sh (New)
Paul Tudor Jones 17,426 sh (+205.72%)
Ray Dalio 84,193 sh (+27.77%)
Dodge & Cox 47,095 sh (+21.93%)
John Buckingham 47,934 sh (+3.06%)
John Rogers 536,616 sh (+2.66%)
Richard Pzena 1,184,416 sh (+2.49%)
Sarah Ketterer 853,150 sh (+1.90%)
First Eagle Investment 1,651,622 sh (+1.73%)
Richard Snow 3,270 sh (+0.77%)
Ruane Cunniff 76,259 sh (+0.32%)
Tom Gayner 574,200 sh (unchged)
Richard Perry 342,277 sh (unchged)
Michael Price 35,000 sh (unchged)
John Hussman 1,325 sh (unchged)
Tweedy Browne Global Value 865,835 sh (unchged)
Warren Buffett 327,100 sh (unchged)
Pioneer Investments 4,202,682 sh (unchged)
RS Investment Management 7,928 sh (unchged)
Brian Rogers 4,633,000 sh (unchged)
George Soros Sold Out
Ken Fisher 10,446,156 sh (-0.02%)
PRIMECAP Management 12,217,813 sh (-0.20%)
Jeff Auxier 93,726 sh (-0.40%)
Bill Frels 1,987,137 sh (-0.45%)
Tweedy Browne 4,163,934 sh (-0.77%)
Murray Stahl 31,318 sh (-1.15%)
Mario Gabelli 366,366 sh (-1.83%)
Prem Watsa 82,850 sh (-2.18%)
Yacktman Fund 3,900,000 sh (-3.70%)
Donald Yacktman 8,651,258 sh (-4.36%)
Robert Olstein 83,000 sh (-4.60%)
Yacktman Focused Fund 3,100,000 sh (-6.06%)
James Barrow 15,350,650 sh (-10.05%)
Jeremy Grantham 12,140,495 sh (-15.09%)
Jim Simons 2,643,000 sh (-15.98%)
First Pacific Advisors 1,473,500 sh (-20.42%)
Steven Romick 1,385,000 sh (-20.86%)
Manning & Napier Advisors, Inc 2,409,406 sh (-49.48%)
HOTCHKIS & WILEY 2,862 sh (-99.80%)
» More
Q4 2014

JNJ Guru Trades in Q4 2014

John Hussman 111,325 sh (+8301.89%)
Joel Greenblatt 790,529 sh (+5420.84%)
Paul Tudor Jones 92,664 sh (+431.76%)
John Rogers 632,132 sh (+17.80%)
Sarah Ketterer 930,583 sh (+9.08%)
RS Investment Management 8,308 sh (+4.79%)
John Buckingham 48,535 sh (+1.25%)
James Barrow 15,491,386 sh (+0.92%)
Murray Stahl 31,382 sh (+0.20%)
Tom Gayner 574,200 sh (unchged)
Warren Buffett 327,100 sh (unchged)
Prem Watsa 82,850 sh (unchged)
Richard Snow 3,270 sh (unchged)
Michael Price 35,000 sh (unchged)
Yacktman Fund 3,900,000 sh (unchged)
Tweedy Browne Global Value 865,835 sh (unchged)
Yacktman Focused Fund 3,100,000 sh (unchged)
Brian Rogers 4,633,000 sh (unchged)
HOTCHKIS & WILEY Sold Out
Steven Romick Sold Out
First Pacific Advisors Sold Out
Richard Pzena 1,183,966 sh (-0.04%)
Ken Fisher 10,424,607 sh (-0.21%)
Ruane Cunniff 75,946 sh (-0.41%)
Jeff Auxier 93,326 sh (-0.43%)
Donald Yacktman 8,611,359 sh (-0.46%)
Tweedy Browne 4,142,445 sh (-0.52%)
PRIMECAP Management 12,143,433 sh (-0.61%)
Manning & Napier Advisors, Inc 2,360,383 sh (-2.03%)
First Eagle Investment 1,616,927 sh (-2.10%)
Bill Frels 1,930,408 sh (-2.85%)
Jeremy Grantham 11,697,741 sh (-3.65%)
Dodge & Cox 44,235 sh (-6.07%)
Mario Gabelli 336,935 sh (-8.03%)
Richard Perry 312,610 sh (-8.67%)
Jim Simons 2,336,700 sh (-11.59%)
Robert Olstein 71,000 sh (-14.46%)
Ray Dalio 64,293 sh (-23.64%)
Pioneer Investments 2,722,369 sh (-35.22%)
» More
Q1 2015

JNJ Guru Trades in Q1 2015

Ray Dalio 268,093 sh (+316.99%)
John Buckingham 61,885 sh (+27.51%)
Manning & Napier Advisors, Inc 2,802,122 sh (+18.71%)
Jeremy Grantham 13,268,899 sh (+13.43%)
Bill Frels 2,118,878 sh (+9.76%)
Joel Greenblatt 833,196 sh (+5.40%)
John Rogers 657,074 sh (+3.95%)
RS Investment Management 8,578 sh (+3.25%)
James Barrow 15,676,362 sh (+1.19%)
First Eagle Investment 1,627,823 sh (+0.67%)
Ken Fisher 10,456,816 sh (+0.31%)
Robert Olstein 71,000 sh (unchged)
Yacktman Fund 3,900,000 sh (unchged)
Richard Snow 3,270 sh (unchged)
Brian Rogers 4,633,000 sh (unchged)
Tweedy Browne Global Value 865,835 sh (unchged)
Tom Gayner 574,200 sh (unchged)
Warren Buffett 327,100 sh (unchged)
Prem Watsa 82,850 sh (unchged)
Richard Perry 312,610 sh (unchged)
Ruane Cunniff 75,937 sh (-0.01%)
Richard Pzena 1,174,016 sh (-0.84%)
Mario Gabelli 333,155 sh (-1.12%)
Donald Yacktman 8,432,672 sh (-2.08%)
Tweedy Browne 4,055,962 sh (-2.09%)
Murray Stahl 30,674 sh (-2.26%)
PRIMECAP Management 11,858,877 sh (-2.34%)
Yacktman Focused Fund 3,000,000 sh (-3.23%)
Pioneer Investments 2,622,793 sh (-3.66%)
Sarah Ketterer 855,044 sh (-8.12%)
Dodge & Cox 39,985 sh (-9.61%)
Michael Price 25,000 sh (-28.57%)
Paul Tudor Jones 56,058 sh (-39.50%)
Jeff Auxier 41,376 sh (-55.67%)
Jim Simons 867,200 sh (-62.89%)
John Hussman 1,325 sh (-98.81%)
» More
» Details

Insider Trades

Latest Guru Trades with JNJ

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Johnson & Johnson

Bill Frels Comments on Johnson & Johnson - Oct 20, 2014

Due to the expansion of its pharmaceutical business, Johnson & Johnson (JNJ) contributed better-than- expected performance during the period. Sales soared by 21% due to almost a dozen recent drug launches and improving profitability, which may support a robust acquisition strategy that could reportedly beat management’s goal of 4.5% growth in annual drug sales through 2017.

From Bill Frels (Trades, Portfolio)' Mairs & Power Growth Fund Q3 2014 Commentary.

Check out Bill Frels latest stock trades

John Rogers' Ariel Fund Comments on Johnson & Johnson - Feb 28, 2014

Johnson & Johnson (JNJ) was a true favorite in the 1990s mega-cap bull market, with its glory days persisting until the end of 2002. From that point through 2010, it hit a relative rough patch. During the 1991 to 2002 period, Johnson & Johnson's revenues gained a remarkable +10.2% annually; in the subsequent period they slipped to a still-solid +6.8%. Its earnings decline was not as steep. The company compounded earnings per share (EPS) at a remarkable +13.6% in the 1990s and early 2000s period before slipping to +10.4% annually in the second era. Its price/earnings (P/E) ratios showcased its increasing popularity in the first period, as well as its fall from grace. Johnson & Johnson's earnings multiple soared from 26.1x in 1991 to a lofty 37.6x in 1998 before drifting down in the bear market to 24.9x at the end of 2002. From there it plummeted, however, to a low of just 12.9x at the end of 2010. Note that while investors chopped its P/E multiple in half from 2002 to 2010, its earnings per share more than doubled...

After its slide in the current century, Johnson & Johnson took the opportunity to reinvigorate itself. Alex Gorsky, who became CEO in 2012, led a major transformation; he charged his new operations head, Sandra Peterson, with structural improvements across the company. On the pharmaceutical side, it refocused its Research & Development (R&D) on blockbuster segments such as anti-coagulants and oncology. In its medical technology division, the company boldly exited the underperforming drug-eluding stent business and deployed foreign cash through the acquisition of high-margin specialty implant maker Synthes, a Swiss company. Johnson & Johnson even bolstered its consumer brands such as Neutrogena and Band-Aid, which offer lower margins but steady cash flows. More importantly, it has gotten past the embarrassing 2010 recalls of the children's versions of Tylenol, Motrin, Zyrtec and Benadryl, and all four are now back on the shelves. We always look forward, even when analyzing a 127-year old company, and at this point see a lean, mean heavyweight ready to compete.

From John Rogers (Trades, Portfolio)' Ariel International Fund & Ariel Global Fund fourth quarter 2013 commentary by Rupal J. Bhansali.

Check out latest stock trades

Top Ranked Articles about Johnson & Johnson

Weekly Insider Sells Highlight: JNJ, TRV, AAL, STJ
According to GuruFocus Insider Data, the largest insider sells during the past week were: Johnson & Johnson, Travelers Companies Inc, American Airlines Group Inc, and St Jude Medical Inc. Read more...
Google Set To Bring In A Difference In The World Of Surgery
The technology giant, Google (GOOG), has always striven to develop the best-in-kind products for the market and is often branded as the tech expert in the industry for its expertise in search optimization and its roaring popularity in the technology space. However, Google’s advent in the healthcare segment has been a sporadic one and does not find much of a mention by the analysts who follow the healthcare segment in the U.S. But currently the Google research team of biologists and chemists are in the top news section as Google is hoping to bring in advanced technology that could help surgeons to perform surgeries in a better way. Let’s get into the facts which have come into the limelight in the past few days with respect to Google’s strategic move to cater to the healthcare domain. Read more...
Guru Ken Fisher’s Top Five Quarterly Stocks
CEO and CIO of Fisher Investments, Ken Fisher, had a pretty busy third quarter. Fisher purchased a total of 47 new stocks. His third quarter portfolio holds 5454 stocks and is valued at over $46.911 billion. The following five stocks represent the five companies where Fisher holds the largest stake in. Read more...
Bill Frels Comments on Johnson & Johnson
Due to the expansion of its pharmaceutical business, Johnson & Johnson (JNJ) contributed better-than- expected performance during the period. Sales soared by 21% due to almost a dozen recent drug launches and improving profitability, which may support a robust acquisition strategy that could reportedly beat management’s goal of 4.5% growth in annual drug sales through 2017. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 17.57
JNJ's P/E(ttm) is ranked higher than
76% of the 469 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 34.80 vs. JNJ: 17.57 )
Ranked among companies with meaningful P/E(ttm) only.
JNJ' s 10-Year P/E(ttm) Range
Min: 10.5  Med: 17.73 Max: 24.45
Current: 17.57
10.5
24.45
Forward P/E 15.58
JNJ's Forward P/E is ranked higher than
70% of the 244 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 23.58 vs. JNJ: 15.58 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 17.80
JNJ's PE(NRI) is ranked higher than
76% of the 465 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 34.50 vs. JNJ: 17.80 )
Ranked among companies with meaningful PE(NRI) only.
JNJ' s 10-Year PE(NRI) Range
Min: 10.5  Med: 17.73 Max: 24.44
Current: 17.8
10.5
24.44
P/B 4.05
JNJ's P/B is ranked lower than
55% of the 679 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.57 vs. JNJ: 4.05 )
Ranked among companies with meaningful P/B only.
JNJ' s 10-Year P/B Range
Min: 2.68  Med: 3.73 Max: 6.21
Current: 4.05
2.68
6.21
P/S 3.82
JNJ's P/S is ranked lower than
52% of the 661 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.54 vs. JNJ: 3.82 )
Ranked among companies with meaningful P/S only.
JNJ' s 10-Year P/S Range
Min: 2.16  Med: 3.21 Max: 4.28
Current: 3.82
2.16
4.28
PFCF 20.42
JNJ's PFCF is ranked higher than
78% of the 289 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 44.65 vs. JNJ: 20.42 )
Ranked among companies with meaningful PFCF only.
JNJ' s 10-Year PFCF Range
Min: 10.29  Med: 16.39 Max: 24.69
Current: 20.42
10.29
24.69
POCF 16.14
JNJ's POCF is ranked higher than
75% of the 399 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 28.21 vs. JNJ: 16.14 )
Ranked among companies with meaningful POCF only.
JNJ' s 10-Year POCF Range
Min: 9  Med: 13.14 Max: 18.86
Current: 16.14
9
18.86
EV-to-EBIT 12.64
JNJ's EV-to-EBIT is ranked higher than
76% of the 480 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.91 vs. JNJ: 12.64 )
Ranked among companies with meaningful EV-to-EBIT only.
JNJ' s 10-Year EV-to-EBIT Range
Min: 8.4  Med: 13.10 Max: 15.7
Current: 12.64
8.4
15.7
PEG 5.09
JNJ's PEG is ranked lower than
65% of the 245 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.89 vs. JNJ: 5.09 )
Ranked among companies with meaningful PEG only.
JNJ' s 10-Year PEG Range
Min: 1.18  Med: 1.57 Max: 246
Current: 5.09
1.18
246
Shiller P/E 20.83
JNJ's Shiller P/E is ranked higher than
76% of the 312 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 40.23 vs. JNJ: 20.83 )
Ranked among companies with meaningful Shiller P/E only.
JNJ' s 10-Year Shiller P/E Range
Min: 13.04  Med: 19.74 Max: 31.27
Current: 20.83
13.04
31.27
Current Ratio 2.44
JNJ's Current Ratio is ranked higher than
53% of the 596 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.29 vs. JNJ: 2.44 )
Ranked among companies with meaningful Current Ratio only.
JNJ' s 10-Year Current Ratio Range
Min: 1.2  Med: 2.03 Max: 2.69
Current: 2.44
1.2
2.69
Quick Ratio 2.10
JNJ's Quick Ratio is ranked higher than
58% of the 596 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.69 vs. JNJ: 2.10 )
Ranked among companies with meaningful Quick Ratio only.
JNJ' s 10-Year Quick Ratio Range
Min: 0.94  Med: 1.61 Max: 2.37
Current: 2.1
0.94
2.37
Days Inventory 132.11
JNJ's Days Inventory is ranked lower than
61% of the 616 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 113.37 vs. JNJ: 132.11 )
Ranked among companies with meaningful Days Inventory only.
JNJ' s 10-Year Days Inventory Range
Min: 99.31  Med: 109.97 Max: 156.36
Current: 132.11
99.31
156.36
Days Sales Outstanding 57.20
JNJ's Days Sales Outstanding is ranked higher than
63% of the 589 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 72.51 vs. JNJ: 57.20 )
Ranked among companies with meaningful Days Sales Outstanding only.
JNJ' s 10-Year Days Sales Outstanding Range
Min: 50.65  Med: 56.33 Max: 61.4
Current: 57.2
50.65
61.4

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.89
JNJ's Dividend Yield is ranked higher than
84% of the 608 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.29 vs. JNJ: 2.89 )
Ranked among companies with meaningful Dividend Yield only.
JNJ' s 10-Year Dividend Yield Range
Min: 1.64  Med: 2.77 Max: 3.84
Current: 2.89
1.64
3.84
Dividend Payout 0.50
JNJ's Dividend Payout is ranked higher than
86% of the 384 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.31 vs. JNJ: 0.50 )
Ranked among companies with meaningful Dividend Payout only.
JNJ' s 10-Year Dividend Payout Range
Min: 0.29  Med: 0.40 Max: 13.89
Current: 0.5
0.29
13.89
Dividend growth (3y) 7.00
JNJ's Dividend growth (3y) is ranked higher than
50% of the 246 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.20 vs. JNJ: 7.00 )
Ranked among companies with meaningful Dividend growth (3y) only.
JNJ' s 10-Year Dividend growth (3y) Range
Min: 7  Med: 13.40 Max: 17.1
Current: 7
7
17.1
Yield on cost (5-Year) 4.11
JNJ's Yield on cost (5-Year) is ranked higher than
87% of the 626 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.34 vs. JNJ: 4.11 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
JNJ' s 10-Year Yield on cost (5-Year) Range
Min: 2.33  Med: 3.94 Max: 5.46
Current: 4.11
2.33
5.46
Share Buyback Rate -1.10
JNJ's Share Buyback Rate is ranked higher than
57% of the 432 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -2.40 vs. JNJ: -1.10 )
Ranked among companies with meaningful Share Buyback Rate only.
JNJ' s 10-Year Share Buyback Rate Range
Min: 2  Med: 0.20 Max: -4.9
Current: -1.1

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 14.02
JNJ's Price/Tangible Book is ranked lower than
87% of the 615 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.30 vs. JNJ: 14.02 )
Ranked among companies with meaningful Price/Tangible Book only.
JNJ' s 10-Year Price/Tangible Book Range
Min: 6.25  Med: 10.18 Max: 18.92
Current: 14.02
6.25
18.92
Price/Projected FCF 1.53
JNJ's Price/Projected FCF is ranked higher than
74% of the 315 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.05 vs. JNJ: 1.53 )
Ranked among companies with meaningful Price/Projected FCF only.
JNJ' s 10-Year Price/Projected FCF Range
Min: 0.84  Med: 1.39 Max: 3.6
Current: 1.53
0.84
3.6
Price/DCF (Earnings Based) 1.69
JNJ's Price/DCF (Earnings Based) is ranked lower than
53% of the 51 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.65 vs. JNJ: 1.69 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.19
JNJ's Price/Median PS Value is ranked higher than
62% of the 608 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.36 vs. JNJ: 1.19 )
Ranked among companies with meaningful Price/Median PS Value only.
JNJ' s 10-Year Price/Median PS Value Range
Min: 0.74  Med: 1.11 Max: 1.88
Current: 1.19
0.74
1.88
Price/Graham Number 3.27
JNJ's Price/Graham Number is ranked lower than
56% of the 367 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.75 vs. JNJ: 3.27 )
Ranked among companies with meaningful Price/Graham Number only.
JNJ' s 10-Year Price/Graham Number Range
Min: 1.95  Med: 3.13 Max: 5.78
Current: 3.27
1.95
5.78
Earnings Yield (Greenblatt) (%) 8.02
JNJ's Earnings Yield (Greenblatt) (%) is ranked higher than
84% of the 698 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.80 vs. JNJ: 8.02 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
JNJ' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 6.4  Med: 7.60 Max: 11.9
Current: 8.02
6.4
11.9
Forward Rate of Return (Yacktman) (%) 9.39
JNJ's Forward Rate of Return (Yacktman) (%) is ranked higher than
56% of the 307 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.25 vs. JNJ: 9.39 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
JNJ' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: 1  Med: 14.90 Max: 18.5
Current: 9.39
1
18.5

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, PFE, RHHBY, NVS, ABT » details
Traded in other countries:JNJB34.Brazil, JNJ.Chile, JNJ.Germany, 0R34.UK, JNJ.Argentina, JNJ.Switzerland, JNJ.Mexico,
Johnson & Johnson was incorporated in the State of New Jersey in 1887. The Company is engaged in the research and development, manufacture and sale of products in the health care field. It is a holding company, which has more than 275 operating companies conducting business in virtually all countries of the world. The Company's operating companies are organized into three business segments: Consumer, Pharmaceutical and Medical Devices and Diagnostics. The Consumer segment includes products used in the baby care, skin care, oral care, wound care and women's health care fields, as well as nutritional and over-the-counter pharmaceutical products. The Baby Care franchise includes the JOHNSON'S Baby line of products. The brands in the Skin Care franchise include the AVEENO; CLEAN & CLEAR; JOHNSON'S Adult; NEUTROGENA; RoC; LUBRIDERM; Beijing Dabao Cosmetics Co., Ltd.; and Vendome product lines. The Oral Care franchise includes the LISTERINE and REACH oral care lines of products. The brands in the Women"s Health franchise are the CAREFREE Pantiliners and STAYFREE sanitary protection products. The nutritional and over-the-counter lines include SPLENDA, No Calorie Sweetener; the family of TYLENOL acetaminophen products; SUDAFED cold, flu and allergy products; ZYRTEC allergy products; MOTRIN IB ibuprofen products; and PEPCID AC Acid Controller from Johnson & Johnson Merck Consumer Pharmaceuticals Co. The Pharmaceutical segment includes products in the following therapeutic areas: anti-infective, antipsychotic, cardiovascular, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, urology and virology. Key products in the Pharmaceutical segment include: REMICADE a treatment for a number of immune-mediated inflammatory diseases; SIMPONI (golimumab), a treatment for adults with moderate to severe rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis and moderately active to severely active ulcerative colitis; STELARA a treatment for adults with moderate to severe plaque psoriasis and active psoriatic arthritis; INCIVO for the treatment of hepatitis C; INTELENCE and PREZISTA, treatments for HIV/AIDS; CONCERTA extended-release tablets CII, a treatment for attention deficit hyperactivity disorder; INVEGA extended-release tablets, for the treatment of schizophrenia and schizoaffective disorder; INVEGA SUSTENNA/XEPLION, for the treatment of schizophrenia in adults; RISPERDAL CONSTA, for the treatment of schizophrenia and for the maintenance treatment of Bipolar I Disorder; VELCADE, a treatment for multiple myeloma; ZYTIGA, a treatment for metastatic castration-resistant prostate cancer; ACIPHEX/PARIET, a proton pump inhibitor co-marketed with Eisai Inc.; PROCRIT, to stimulate red blood cell production; and XARELTO, an oral anticoagulant for the prevention of deep vein thrombosis (DVT), which may cause to pulmonary embolism (PE) in patients undergoing hip or knee repl
» More Articles for JNJ

Headlines

Articles On GuruFocus.com
The Surprising Llink Between Volatility And Returns Jun 22 2015 
Follow Bill Ackman in Valeant Pharmaceuticals Jun 19 2015 
Johnson & Johnson Looks Attractive Jun 12 2015 
What The Great Recession Taught Me About Dividend Growth Investing Jun 11 2015 
How Warren Buffett Interprets Financial Statements Part 1 Jun 10 2015 
Bill Frels Adds to 63 Existing Stakes in First Quarter Jun 08 2015 
Joel Greenblatt Adds to His Position in Johnson and Johnson Jun 11 2015 
Three Reasons Why Retired Investors Should Put Maximum Focus and Weight On Dividends May 29 2015 
James Barrow increases his position in Johnson and Johnson May 28 2015 
11 Reasons to be a Dividend Growth Investor May 27 2015 

More From Other Websites
Investigational HIV Vaccine Regimen Shows Encouraging Results in Non-Human Primates Jul 02 2015
CNBC update: Fight against AIDS Jul 02 2015
J&J vaccine completely prevented HIV in half of monkeys in trial Jul 02 2015
J&J vaccine completely prevented HIV in half of monkeys in trial Jul 02 2015
What's behind big put sale in JNJ Jul 02 2015
Gilead Submits Marketing Application for HIV Drug to FDA - Analyst Blog Jul 02 2015
Global pharma firms grilled about tax in Australia Jul 02 2015
3 Reasons Johnson & Johnson Stock Could Rise Jul 01 2015
3 Reasons Why Investors Should Keep Johnson & Johnson (JNJ) Stock - Stocks in the News Jul 01 2015
10 Worst Health Care Stocks in the S&P 500 Jul 01 2015
Greece crisis hits shares of some, but not all, U.S. multinationals Jun 29 2015
The six best sectors for 2015’s second half Jun 25 2015
Johnson & Johnson Consumer Companies, Inc. Collaborates with Walgreens to Improve Health Outcomes Jun 25 2015
Could ASCO's New Ratings Boost J&J's Sales? Jun 23 2015
Will the ad industry’s new Sheryl Sandberg-backed award go far enough on gender equality? Jun 23 2015
10 Dream Mergers; Fed's Greek Problem; Up Side of Negativity: Jim Cramer's Best Blogs Jun 19 2015
Business of bacteria Jun 19 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK